Establishment Labs (NASDAQ:ESTA) Upgraded at Wall Street Zen

Establishment Labs (NASDAQ:ESTA) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other equities research analysts also recently weighed in on ESTA. Stephens reiterated an “overweight” rating and set a $52.00 target price on shares of Establishment Labs in a research note on Thursday, March 6th. BTIG Research initiated coverage on Establishment Labs in a research note on Friday, May 16th. They set a “buy” rating and a $62.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $48.00 price objective on shares of Establishment Labs in a research report on Friday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $52.40.

Establishment Labs Stock Performance

Shares of ESTA opened at $37.44 on Friday. The company’s 50 day simple moving average is $33.99 and its 200-day simple moving average is $37.23. The firm has a market cap of $1.08 billion, a PE ratio of -14.51 and a beta of 0.74. Establishment Labs has a 12-month low of $26.56 and a 12-month high of $52.41. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The firm had revenue of $41.38 million during the quarter, compared to analysts’ expectations of $41.15 million. During the same quarter in the prior year, the business earned ($0.58) EPS. Establishment Labs’s quarterly revenue was up 11.3% compared to the same quarter last year. As a group, equities analysts predict that Establishment Labs will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

Hedge funds have recently made changes to their positions in the company. Brown Advisory Inc. increased its stake in shares of Establishment Labs by 23.1% during the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company’s stock worth $107,729,000 after acquiring an additional 438,057 shares during the period. Capital Research Global Investors boosted its holdings in Establishment Labs by 29.3% in the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company’s stock valued at $88,064,000 after purchasing an additional 433,484 shares in the last quarter. Nantahala Capital Management LLC increased its position in Establishment Labs by 7.2% during the 1st quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company’s stock worth $72,390,000 after purchasing an additional 119,574 shares during the period. Findell Capital Management LLC raised its stake in shares of Establishment Labs by 28.5% during the 4th quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company’s stock worth $62,032,000 after buying an additional 298,380 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its stake in shares of Establishment Labs by 7.4% during the 1st quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company’s stock worth $33,763,000 after buying an additional 56,756 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.